Daxor logo thumbnail.png
Daxor Corporation Joins the Heart Failure Society of America (HFSA) as a Corporate Member
19 janv. 2023 08h00 HE | Daxor Corporation
Oak Ridge, TN, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces joining the Heart Failure Society of...
Daxor logo thumbnail.png
Daxor Corporation to Exhibit at the Society for Critical Care Medicine 2023 Critical Care Congress
13 janv. 2023 08h00 HE | Daxor Corporation
Oak Ridge, TN, Jan. 13, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be presenting at the Society for...
Daxor logo thumbnail.png
Newly Published Study Proves Value and Clinical Benefit of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Evaluation of Heart Failure
03 janv. 2023 08h00 HE | Daxor Corporation
Study Shows Direct Volume Measurement’s Accuracy Compared to Pressure Measures Oak Ridge, TN, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume...
Daxor logo thumbnail.png
Daxor Corporation Announces Closing of $2.1 million Underwritten Public Offering and Exercise of Over-Allotment Option
17 nov. 2022 11h07 HE | Daxor Corporation
Oak Ridge, TN, Nov. 17, 2022 (GLOBE NEWSWIRE) -- DAXOR CORPORATION (Nasdaq: DXR) (“Daxor”, or the “Company”), the global leader in blood volume measurement technology, today announced the closing of...
Daxor logo thumbnail.png
Daxor Corporation Announces Pricing of $2.0 million Underwritten Public Offering
15 nov. 2022 08h45 HE | Daxor Corporation
Oak Ridge, TN, Nov. 15, 2022 (GLOBE NEWSWIRE) -- DAXOR CORPORATION (Nasdaq: DXR) (“Daxor”, or the “Company”), the global leader in blood volume measurement technology, today announced the pricing of...
Daxor logo thumbnail.png
Daxor Corporation Announces Launch of Proposed Underwritten Public Offering
14 nov. 2022 17h03 HE | Daxor Corporation
Oak Ridge, TN, Nov. 14, 2022 (GLOBE NEWSWIRE) -- DAXOR CORPORATION (Nasdaq: DXR) (“Daxor”, or the “Company”), the global leader in blood volume measurement technology, today announced that it has...
Daxor logo thumbnail.png
Live Webinar by MedAxiom Features Best Practices Using Daxor’s Blood Volume Analysis (BVA-100®) to Improve Heart Failure Outcomes and Reduce Costs
10 nov. 2022 08h00 HE | Daxor Corporation
Oak Ridge, TN, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces Daxor’s BVA-100 diagnostic will be...
54741_Image_jpeg.jpg
Newly Published Study Demonstrates Significant Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Evaluation of Heart Failure
03 nov. 2022 08h00 HE | Daxor Corporation
Study Highlighted That Only The BVA-100 Accurately Measures Volume Derangements Compared to Commonly Used Surrogates Oak Ridge, TN, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq:...
54741_Image_jpeg.jpg
Daxor Corporation to Exhibit at American Heart Association’s Scientific Sessions 2022
31 oct. 2022 08h00 HE | Daxor Corporation
Oak Ridge, TN, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be attending the American Heart...
54741_Image_jpeg.jpg
Expert Panel Calls for Use of Blood Volume Measurement to Assess Heart Failure Patients at Key Scientific Meeting
05 oct. 2022 08h30 HE | Daxor Corporation
Evidence Presented Utilizing Daxor’s BVA-100® Blood Volume Test Oak Ridge, TN, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement...